Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals

AIDS

Volumn 24, Issue 1, 2010, Pages 109-114

  Ouyang, David W ^a   Brogly, Susan B ^b   Lu, Ming ^c   Shapiro, David E ^b   Hershow, Ronald C ^d   French, Audrey L ^e   Leighty, Robert M ^c   Thompson, Bruce ^c   Tuomala, Ruth E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c Clinical Trials & Surveys Corp   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Jr Hospital of Cook County   (United States)

Author keywords

AIDS; Antiretroviral therapy; Hepatotoxicity; HIV; Nevirapine; Pregnancy; Women

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIVER ENZYME; NEVIRAPINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; PREGNANT WOMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REGRESSION ANALYSIS;

EID: 73649143152     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283323941     Document Type: Article

References (23)

1. Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HJ Jr, Powderly WG, et al. Sex differences in nevir-apine rash. Clin Infect Dis 2001; 32:124-129.
2. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
3. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34:S21-S33.
4. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
5. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36:772-776.
6. Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Cynecol 2005; 106:1032-1038.
7. Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260.
8. Langlet P, Guillaume MP, Devriendt J, Deprez C, Vokaer A, De Koster E, et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case. Gastroenterology 2000; 118:A1461.
9. Lyons F, Hopkins S, McGreary A, Sheehan G, Bergin C, Mulcahy F. Nevirapine tolerability in HIV infected women in pregnancy: a word of caution [abstract #LB27]. In: 2nd IAS Conference on HIV Pathogenesis and Treatment; 13-16 July 2003; Paris.
10. Boehringer Ingelheim Company. VIRAMUNE (nevirapine) package insert. Ingelheim, Germany; January 2005.
11. Food and Drug Administration. FDA Public Health Advisory for nevirapine (viramune). 19 January 2005. http://www.fda.gov/ cder/drug/advisory/nevirapine. htm.
12. Sheon AR, Fox HE, Rich KC, Stratton P, Diaz C, Tuomala R, et al. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Womens Health 1996; 5:69-78.
13. Brogly S, Read JS, Shapiro D, Stek A, Tuomala R. Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses 2007; 23:51-53.
14. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
15. Therneau TM, Grambasch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2001.
16. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44: 371-376.
17. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapine-containing antire-troviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006; 7:338-344.
18. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithong-wongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8:357-366.
19. Joao EC, Calvet GA, Menezes JA, D'Ippolito MM, Cruz MLS, Salgado LAT, Matos HJ. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194:199-202.
20. Natarajan U, Pym A, McDonald C, Velisetty P, Edwards SG, Hay P, et al. Safety of nevirapine in pregnancy. HIV Med 2007; 8:64-69.
21. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1M0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
22. Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 2002; 51:876-880.
23. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetrical outcomes and few maternal toxi-cities are associated with antiretroviral therapy including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449-473.